# A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21

> **NCT05357560** · PHASE1 · COMPLETED · sponsor: **University of Oxford** · enrollment: 107 (actual)

## Conditions studied

- Malaria, Plasmodium Falciparum

## Interventions

- **BIOLOGICAL:** Matrix-M with RH5.2 VLP and/or R21

## Key facts

- **NCT ID:** NCT05357560
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-10
- **Primary completion:** 2025-12-11
- **Final completion:** 2025-12-11
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2026-05-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05357560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05357560, "A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT05357560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*